Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pridopidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 14/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pridopidine SCHEMBL29664816 | 1.00 | DRD2 (1.00) | DRD2SIGMAR1DRD3SLC6A4HTR6 | |
| Pridopidine SCHEMBL15007479 | 0.99 | DRD2 (0.97) | DRD2SIGMAR1DRD3SLC6A4HTR6 | |
| Pridopidine SCHEMBL2370301 | 0.99 | DRD2 (0.97) | DRD2SIGMAR1DRD3SLC6A4HTR6 | |
| SCHEMBL18396165 | 0.95 | DRD2 (0.90) | DRD2SIGMAR1DRD3SLC6A4HTR6 | |
| SCHEMBL4824015 | 0.92 | DRD2 (0.85) | DRD2SIGMAR1DRD3 | |
| SCHEMBL4824639 | 0.89 | DRD2 (0.80) | DRD2SIGMAR1DRD3HTR6 | |
| SCHEMBL17364137 | 0.86 | DRD2 (0.75) | DRD2SIGMAR1DRD3SLC6A4HTR6 | |
| SCHEMBL29354894 | 0.86 | DRD2 (0.75) | DRD2SIGMAR1DRD3SLC6A4HTR6 | |
| SCHEMBL873812 | 0.86 | DRD3 (1.00) | DRD2SIGMAR1DRD3 | |
| SCHEMBL873549 | 0.86 | DRD3 (1.00) | DRD2SIGMAR1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 947 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741013-A2 | COMBINATION THERAPY FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS USING PRIDOPIDINE AND ANOTHER ACTIVE AGENT | Prilenia Neurotherapeutics Ltd. (IL) | 2026-05-13 | — | — | EP | claimed |
| US-12616687-B2 | Treatment of viral infection, disease or disorder using a selective sir agonist | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2026-05-05 | — | — | US | claimed |
| WO-2026090434-A1 | METHODS OF TREATING AND/OR PREVENTING POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260097017-A1 | TASIPIMIDINE AND CYP2D6 INHIBITOR COMBINATION TREATMENT | ORION CORPORATION (FI) | 2026-04-09 | — | — | US | claimed |
| US-20260091028-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2026-04-02 | — | — | US | claimed |
| EP-4103179-B1 | COMBINATION THERAPY FOR USE IN TREATING AMYOTROPHIC LATERAL SCLEROSIS USING PRIDOPIDINE AND CNM-AU8 NANOCRYSTALLINE GOLD | Prilenia Neurotherapeutics Ltd (IL) | 2026-03-11 | — | — | EP | claimed |
| US-20260060967-A1 | USE OF PRIDOPIDINE FOR TREATING HUNTINGTON DISEASE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2026-03-05 | — | — | US | claimed |
| US-12564582-B2 | Use of pridopidine for treating dystonias | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2026-03-03 | — | — | US | claimed |
| EP-4695613-A2 | METHODS OF MODIFYING NEURONS IN VIVO TO TREAT AND/OR PREVENT AMYOTROPHIC LATERAL SCLEROSIS (ALS) | Yale University (US) | 2026-02-18 | — | — | EP | claimed |
| US-12551474-B2 | Use of pridopidine for the treatment of fragile X syndrome | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2026-02-17 | — | — | US | claimed |
| WO-2012028635-A1 | DEUTERATED ANALOGS OF PRIDOPIDINE USEFUL AS DOPAMINERGIC STABILIZERS | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-03-08 | — | — | WO | claimed |
| WO-2011107583-A1 | SUBSTITUTED 4-PHENYL-N-ALKYL-PIPERIDINES FOR PREVENTING ONSET OR SLOWING PROGRESSION OF NEURODEGENERATIVE DISORDERS | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-09-09 | — | — | WO | claimed |
| US-20100197712-A1 | USE OF DOPAMINE STABILIZERS | A. CARLSSON RESEARCH AB (SE) | 2010-08-05 | — | — | US | claimed |
| EP-2170327-A2 | USE OF DOPAMINE STABILIZERS | A.Carlsson Research AB (SE) | 2010-04-07 | — | — | EP | claimed |
| EP-2030619-A1 | Use of dopamine stabilizers | A.Carlsson Research AB (SE) | 2009-03-04 | — | — | EP | claimed |
| WO-2008155357-A2 | USE OF DOPAMINE STABILIZERS | A. CARLSSON RESEARCH AB (SE) | 2008-12-24 | — | — | WO | claimed |
| EP-1240142-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2005-10-19 | — | — | EP | claimed |
| US-6903120-B2 | A 4-(phenyl-N- alkyl)-piperidine derivatives for treatment of central nervous system disorders, Parkinson disease, anxiety, dyskinesias, dystonias, Tourette's disease, psychoses, hallucinoses, sleep disorder, autism | A. CARLSSON RESEARCH AB (SE) | 2005-06-07 | — | — | US | claimed |
| EP-1428822-A2 | 1-phenylpiperazine derivative as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-06-16 | — | — | EP | claimed |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2003-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060967-A1 | USE OF PRIDOPIDINE FOR TREATING HUNTINGTON DISEASE | HTT, DRD2, HTR2C | DRD2 2/4885SIGMAR1 342/4885DRD3 24/4885 |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | DRD2 16/4885SIGMAR1 9/4885DRD3 8/4885 |
| US-20260091028-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE | SMN1; SMN2, SNCA, PRNP | DRD2 37/4885SIGMAR1 120/4885DRD3 336/4885 |
| US-20100197712-A1 | USE OF DOPAMINE STABILIZERS | COMT, SNCA, DBH | DRD2 5/4885SIGMAR1 200/4885DRD3 20/4885 |
| US-20260097017-A1 | TASIPIMIDINE AND CYP2D6 INHIBITOR COMBINATION TREATMENT | SLC6A2, ADRB2, ADRA2C | DRD2 159/4885SIGMAR1 197/4885DRD3 1057/4885 |
| US-12564582-B2 | Use of pridopidine for treating dystonias | KCND2, HTT, BTD | DRD2 17/4885SIGMAR1 395/4885DRD3 233/4885 |
| US-12551474-B2 | Use of pridopidine for the treatment of fragile X syndrome | MECP2, DNMT3A, KCND2 | DRD2 33/4885SIGMAR1 1587/4885DRD3 312/4885 |
| US-12616687-B2 | Treatment of viral infection, disease or disorder using a selective sir agonist | TMPRSS11D, OXTR, CRHR2 | DRD2 37/4885SIGMAR1 47/4885DRD3 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.